欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (4): 401-405.doi: 10.12092/j.issn.1009-2501.2024.04.006

• 慢性气道疾病药物治疗新进展 • 上一篇    下一篇

一种治疗慢性阻塞性气道疾病的新药:那伐芬特罗

刘育如1,2,吴雯雯1,2,王刚1,2   

  1. 1四川大学华西医院呼吸与危重症医学科 呼吸疾病临床医学研究中心,成都  610041,四川;2呼吸和共病全国重点实验室,成都  610041,四川

  • 收稿日期:2023-08-01 修回日期:2023-10-13 出版日期:2024-04-26 发布日期:2024-03-25
  • 通讯作者: 王刚,男,博士,教授,博士生导师,研究方向:支气管哮喘。 E-mail: wong-gang@126.com
  • 作者简介:刘育如,女,硕士,研究方向:支气管哮喘。 E-mail: 13569077229@163.com
  • 基金资助:
    国家自然科学基金资助项目(82370044);国家自然科学基金国际合作重点项目(81920108002);四川大学华西医院学科卓越1.3.5临床研究孵化项目(2018HXFH016);四川省科技厅(2022YFS0263);成都市科技局国际合作项目(2021-GH03-00007-HZ)

Navafenterol, a new drug for the treatment of chronic obstructive airway disease

LIU Yuru1,2, WU Wenwen1,2, WANG Gang1,2   

  1. 1Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; 2State Key Laboratory of Respiratory Health and Multimorbidity, Chengdu 610041, Sichuan, China
  • Received:2023-08-01 Revised:2023-10-13 Online:2024-04-26 Published:2024-03-25

摘要:

那伐芬特罗(navafenterol)是一单分子且同时具备毒蕈碱受体拮抗和β2受体激动效应的新型化合物,正开发用于治疗慢性阻塞性肺疾病和哮喘等慢性阻塞气道疾病。该药可显著改善肺功能,且安全性和耐受性良好,常见治疗后不良事件包括头痛、鼻咽炎、头晕等,有可能成为慢性阻塞性气道疾病下一代支气管扩张剂。本文就那伐芬特罗的基础和临床研究现状等进行介绍。

关键词: navafenterol, 慢性阻塞性肺疾病, 哮喘, 支气管扩张剂, 毒蕈碱受体拮抗剂, β2受体激动剂

Abstract:

Navafenterol is a new compound with both muscarinic receptor antagonist and β2 receptor agonist effects in a single molecule, who is being developed for the treatment of chronic obstructive airway disease such as chronic obstructive pulmonary disease and asthma. These pilot clinical studies found that it can significantly improve lung function and symptoms, and is safe and well tolerated. Common treatment emergent adverse events include headache, nasopharyngitis, and dizziness. It may become a next-generation bronchodilator for chronic obstructive airway disease. This review introduced the prospective of Navafenterol.

Key words: navafenterol, chronic obstructive pulmonary disease, asthma, bronchodilator, muscarinic receptor antagonist, β2 receptor agonist 

中图分类号: